Janux Therapeutics, Inc. (JANX) AI Stock Analysis

Janux Therapeutics, Inc. is a biopharmaceutical firm founded in 2017 and based in La Jolla, California. The company specializes in the development of innovative cancer therapeutics using its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology. Janux Therapeutics' lead TRACTr product candidates are in preclinical or discovery stages, targeting markers such as prostate-specific membrane antigen, epidermal growth factor receptor (EGFR), and trophoblast cell surface antigen 2. In addition, the company is developing a Tumor Activated Immunomodulator (TRACIr), a costimulatory bispecific candidate targeting PD-L1 and CD28 to enhance the anti-tumor activity of T cells.

Annual revenue grew from $3.6M in FY2021 to $10.0M in FY2025, yielding a 5-year revenue CAGR of 92.3%. However, top-line performance has fluctuated, with revenue falling 5.6% in FY2025 after rising 31.0% in FY2024 to $10.6M. Operating expenses expanded as R&D expense reached $125.9M in FY2025, leading to an operating margin of -1576.7% and a net loss of -$113.6M. For the trailing twelve months ended June 30, 2026, revenue was $24.0M with an EPS of -$1.64, supported by quarterly revenue growth of 2177.9% year-over-year in the latest quarter.

As of June 30, 2026, Janux Therapeutics held $970.9M in cash and short-term investments against $21.0M in total debt, resulting in net cash of $949.9M. The current ratio stood at 16.35, and the debt-to-equity ratio was 0.02 against shareholders' equity of $928.0M. In FY2025, operating cash flow was -$82.2M and free cash flow was -$83.3M. Cash outflows included capital expenditures of $1.0M and share buybacks of $347,000.

Janux Therapeutics trades at a price-to-sales ratio of 42.1x, significantly higher than the 4.1x median of its US-listed Healthcare peers. Its enterprise value to revenue multiple is 2.5x, and its price-to-book ratio is 1.1x. Over the past year, the stock fell 39.3%, underperforming the S&P 500 (SPY) return of 16.8%. Over a 5-year period, JANX returned -21.9% compared to an 83.0% gain for the S&P 500.

Wall Street coverage includes 14 Strong Buy, 2 Buy, 1 Hold, and 1 Sell rating. The mean price target is $36.24, representing an upside of 119.5% from the last close of $16.51. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $29.4M and an EPS of -$1.73. For the following fiscal year, 13 analysts anticipate revenue of $8.1M and an EPS of -$2.62. Janux Therapeutics has beaten EPS estimates in 3 of the last 4 quarters, with its next earnings date scheduled for November 5, 2026.

This page is an AI-written research summary of Janux Therapeutics, Inc. (JANX). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: JANX income statement, JANX balance sheet, JANX key metrics, JANX analyst forecast, JANX chart. See the JANX stock overview for the latest quote and news.